Pandemic Watch: Be Glad You Live in a First-World Country
Well, maybe “glad” is a little too strong in this case. Looks like there’s not going to be enough H1N1 influenza vaccine to go around, at least not in poorer and developing nations. There are problems with the process of making the vaccine to fight the novel strain of flu, and it appears manufacturers are only getting yields of about half what they get from the manufacture of seasonal flu vaccines. Since most vaccines are manufactured in First World nations, their orders will be filled first, according to the World Health Organization.
From The Canadian Press, Sunday, July 12, via ProMed:
Swine flu vaccine production has hit a snag, with manufacturers reporting a disappointingly low yield when vaccines viruses are grown in eggs. The World Health Organization [WHO] says so far the yield for egg-based production is half or less than what manufacturers get when they make vaccine to protect against seasonal H1N1 viruses. The lion’s share of influenza vaccine is made by companies that grow the viruses in eggs.
New seed strains are being made in the hopes of increasing the vaccine yield, a report by the WHO’s vaccine chief, Dr. Marie-Paule Kieny, says. But if the yield cannot be increased, it will slow the rate at which pandemic vaccine comes out of the production pipeline, adding to the time it takes to protect populations in countries like Canada that have purchased vaccine. And countries that haven’t preordered pandemic vaccine would face substantial delays before manufacturers have product to sell to them.
“There’s nothing to suggest it will take longer to make vaccine, if in fact everything goes as planned. The question is: How much?” says Dr. Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota. “There is nothing magical about making this virus. The questions will be: How much? When? and Where will it be available?”
The yield problem is revealed in presentations WHO staff made to last week’s special meeting of the expert panel that advises the Geneva-based global health agency on vaccine issues. The body — called the Strategic Advisory Group of Experts on immunization, or SAGE — was convened to give WHO counsel on a variety of questions about pandemic vaccine use. Those include which groups should be given priority when vaccine becomes available and whether the WHO should recommend companies use adjuvants, which are boosting compounds that could help stretch limited supplies.


